Tumor cell-specific transgene expression prevents liver toxicity of the adeno-HSVtk/GCV approach

Gene Therapy

Volumn 5, Issue 10, 1998, Pages 1363-1371

  Brand, K ^a   Loser P ^b   Arnold, W ^c   Bartels, Th ^d   Strauss, M ^a,c,e  

^a HUMBOLDT UNIVERSITY   (Germany)

^b HepaVec AG   (Germany)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^d FREIE UNIVERSITÄT BERLIN   (Germany)

^e DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

Adenovirus; CEA promoter; Ganciclovir; HSVtk; Toxicity

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; GANCICLOVIR; THYMIDINE KINASE;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBIOTIC SENSITIVITY; ARTICLE; CELL SPECIFICITY; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOTOXICITY; EXPRESSION VECTOR; GENE EXPRESSION REGULATION; GENE TRANSFER; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; LIVER CELL; LIVER TOXICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; RAT; TRANSGENE; TUMOR CELL;

EID: 0031788861     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300728     Document Type: Article

References (31)

1. Moolten FL, Wells JM, Heyman RA, Evans RM. Lymphoma regression induced by ganciclovir in mice bearing a herpes thymidine kinase transgene. Hum Gene Ther 1990; 1: 125-134.
2. Deonarain MP, Spooner RA, Epenetos AA. Genetic delivery of enzymes for cancer therapy. Gene Therapy 1995; 2: 235-244.
3. Freeman SM et al. The 'bystander effect': tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53: 5274-5283.
4. Chen SH et al. Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc Natl Acad Sci USA 1995; 92: 2577-2581.
5. O'Malley BW, Chen S-H, Schwartz MR, Woo SLC Adenovirus-mediated gene therapy for human head and neck squamous cell cancer in a nude mouse model. Cancer Res 1995; 55: 1080-1085.
6. Brand K et al. Liver-associated toxicity of the HSVtk/GCV approach and adenoviral vectors. Cancer Gene Ther 1997; 4: 9-16.
7. Maron A et al. Differential toxicity of ganciclovir for rat neurons and astrocytes in primary culture following adenovirus-mediated transfer of the HSVtk gene. Gene Therapy 1997; 4: 25-31.
8. Qian C et al. Gene transfer and therapy with adenoviral vectors in rats with diethylnitrosamine-induced hepatocellullar carcinoma. Hum Gene Ther 1997; 8: 349-358.
9. van der Eb MM et al. Severe hepatic dysfunction after adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene and ganciclovir administration. Gene Therapy 1998; 5: 451-458.
10. Bookstein R et al. P53 gene therapy in vivo of hepatocellular and liver metastatic colorectal cancer Semin Oncol 1996; 23: 66-77.
11. Thompson JA, Grunert F, Zimmermann W. Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J Clin Lab Anal 1991; 5: 344-366.
12. Richards CA, Austin EA, Huber BE. Transcriptional regulatory sequences of Carcinoembryonic antigen: identification and use with cytosine deaminase for tumor-specific gene therapy. Hum Gene Ther 1995; 6: 881-893.
13. Schrewe H et al. Cloning of the complete gene for carcinoembryonic antigen: analysis of its promoter indicates a region conveying cell type-specific expression. Mol Cell Biol 1990; 10: 2738-2748.
14. DiMaio JM et al. Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo. Surgery 1994; 116: 205-213.
15. Osaki T et al. Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by cell type-specific expression of herpes simplex virus thymidine kinase gene. Cancer Res 1994; 54: 5258-5261.
16. Li Q et al. Assessment of recombinant adenoviral vectors for hepatic gene therapy. Hum Gene Ther 1993; 4: 403-409.
17. Chen L et al. Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/MUC1 promoter. J Clin Invest 1995; 96: 2775-2782.
18. Connelly S, Gardner JM, McClelland A, Kaleko M. High-level tissue-specific expression of functional human factor VIII in mice. Hum Gene Ther 1996; 7: 183-195.
19. Imler JL et al. Targeting cell-specific gene expression with an adenovirus vector containing the lacZ gene under the control of the CFTR promoter. Gene Therapy 1996; 3: 49-58.
20. Sandig V et al. HBV-derived promoters direct liver-specific expression of an adenovirally transduced LDL receptor gene. Gene Therapy 1996; 3: 1002-1009.
21. Siders WM, Halloran PJ, Fenton RG. Transcriptional targeting of recombinant adenoviruses to human and murine melanoma cells. Cancer Res 1996; 56: 5638-5646.
22. Tanaka T et al. Adenovirus-mediated gene therapy of gastric carcinoma using cancer-specific gene expression in vivo. Biochem Biophys Res Commun 1997; 231: 775-779.
23. Telenti A, Smith TF. Screening with a shell vial assay for antiviral activity against cytomegalovirus. Diagn Microbiol Infect Dis 1989; 12: 5-8.
24. Black ME, Newcomb TG, Wilson HM, Loeb LA. Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy. Proc Natl Acad Sci USA 1996; 93: 3525-3529.
25. Stratford-Perricaudet LO, Makeh I, Perricaudet M, Briand P. Widespread long-term gene transfer to mouse skeletal muscles and heart. J Clin Invest 1992; 90: 525-530.
26. Bert AJ, Haddara W, Prevec L, Graham FL. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci USA 1994; 91: 8802-8806.
27. McGrory WJ, Bautista DS, Graham FL. A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5. Virology 1988; 163: 614-617.
28. Precious B, Russell WC. Growth, purification and titration of adenoviruses. In: Mahy BWJ (ed). Virology - A Practical Approach. IRL Press: Oxford, Washington DC, 1985, pp 193-206.
29. Los G et al. Intraperitoneal tumor growth and chemotherapy in a rat model. Eur J Cancer Clin Oncol 1989; 25: 1857-1866.
30. Zedeck MS, Sternberg SS. A model system for studies of colon carcinogenesis: tumor induction by a single injection of methylazoxymethanol acetate. J Natl Cancer Inst 1974; 53: 1419-1421.
31. Glatt HR, Billings R, Platt KL, Oesch F. Improvement of the correlation of bacterial mutagenicity with carcinogenicity of benzo(a)pytene and four of its major metabolites by activation with intact pyrene cells instead of homogenate. Cancer Res 1981; 41: 270-277.